vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Camden Property Trust (CPT). Click either name above to swap in a different company.

Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.3M, roughly 1.5× Camden Property Trust). Camden Property Trust runs the higher net margin — 2954.1% vs -766.0%, a 3720.1% gap on every dollar of revenue. On growth, Camden Property Trust posted the faster year-over-year revenue change (243.0% vs -79.3%). Over the past eight quarters, Camden Property Trust's revenue compounded faster (102.8% CAGR vs -24.6%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Camden Property Trust is a publicly traded real estate investment trust that invests in apartments in the United States. As of December 31, 2023, the company owned interests in 176 apartment communities containing 59,800 apartment homes in the United States. It is the 14th largest owner of apartments in the United States.

ACLX vs CPT — Head-to-Head

Bigger by revenue
ACLX
ACLX
1.5× larger
ACLX
$8.1M
$5.3M
CPT
Growing faster (revenue YoY)
CPT
CPT
+322.3% gap
CPT
243.0%
-79.3%
ACLX
Higher net margin
CPT
CPT
3720.1% more per $
CPT
2954.1%
-766.0%
ACLX
Faster 2-yr revenue CAGR
CPT
CPT
Annualised
CPT
102.8%
-24.6%
ACLX

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
ACLX
ACLX
CPT
CPT
Revenue
$8.1M
$5.3M
Net Profit
$-62.3M
$156.0M
Gross Margin
Operating Margin
-847.6%
Net Margin
-766.0%
2954.1%
Revenue YoY
-79.3%
243.0%
Net Profit YoY
-765.1%
283.5%
EPS (diluted)
$-1.13
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
CPT
CPT
Q4 25
$5.3M
Q3 25
$2.6M
Q2 25
$2.6M
Q1 25
$8.1M
$2.5M
Q4 24
$15.3M
$1.5M
Q3 24
$26.0M
$1.7M
Q2 24
$27.4M
$2.6M
Q1 24
$39.3M
$1.3M
Net Profit
ACLX
ACLX
CPT
CPT
Q4 25
$156.0M
Q3 25
$108.9M
Q2 25
$80.7M
Q1 25
$-62.3M
$38.8M
Q4 24
$-47.1M
$40.7M
Q3 24
$-25.9M
$-4.2M
Q2 24
$-27.2M
$42.9M
Q1 24
$-7.2M
$83.9M
Operating Margin
ACLX
ACLX
CPT
CPT
Q4 25
Q3 25
Q2 25
Q1 25
-847.6%
Q4 24
-348.2%
Q3 24
-129.1%
Q2 24
-127.8%
Q1 24
-40.3%
Net Margin
ACLX
ACLX
CPT
CPT
Q4 25
2954.1%
Q3 25
4246.9%
Q2 25
3063.8%
Q1 25
-766.0%
1561.0%
Q4 24
-308.4%
2642.3%
Q3 24
-99.4%
-246.3%
Q2 24
-99.3%
1646.9%
Q1 24
-18.3%
6533.4%
EPS (diluted)
ACLX
ACLX
CPT
CPT
Q4 25
$1.44
Q3 25
$1.00
Q2 25
$0.74
Q1 25
$-1.13
$0.36
Q4 24
$-0.87
$0.37
Q3 24
$-0.48
$-0.04
Q2 24
$-0.51
$0.40
Q1 24
$-0.14
$0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
CPT
CPT
Cash + ST InvestmentsLiquidity on hand
$543.3M
$25.2M
Total DebtLower is stronger
$3.9B
Stockholders' EquityBook value
$416.9M
$4.4B
Total Assets
$648.1M
$9.0B
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
CPT
CPT
Q4 25
$25.2M
Q3 25
$25.9M
Q2 25
$33.1M
Q1 25
$543.3M
$26.2M
Q4 24
$587.4M
$21.0M
Q3 24
$574.3M
$31.2M
Q2 24
$516.7M
$93.9M
Q1 24
$573.9M
$92.7M
Total Debt
ACLX
ACLX
CPT
CPT
Q4 25
$3.9B
Q3 25
$3.7B
Q2 25
$3.8B
Q1 25
$3.7B
Q4 24
$3.5B
Q3 24
$3.5B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
ACLX
ACLX
CPT
CPT
Q4 25
$4.4B
Q3 25
$4.5B
Q2 25
$4.6B
Q1 25
$416.9M
$4.6B
Q4 24
$454.8M
$4.7B
Q3 24
$483.0M
$4.7B
Q2 24
$487.2M
$4.9B
Q1 24
$496.6M
$4.9B
Total Assets
ACLX
ACLX
CPT
CPT
Q4 25
$9.0B
Q3 25
$9.1B
Q2 25
$9.1B
Q1 25
$648.1M
$9.0B
Q4 24
$711.3M
$8.9B
Q3 24
$764.9M
$8.9B
Q2 24
$734.3M
$9.1B
Q1 24
$779.7M
$9.1B
Debt / Equity
ACLX
ACLX
CPT
CPT
Q4 25
0.89×
Q3 25
0.82×
Q2 25
0.83×
Q1 25
0.81×
Q4 24
0.75×
Q3 24
0.73×
Q2 24
0.73×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
CPT
CPT
Operating Cash FlowLast quarter
$-63.1M
$826.6M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
Cash ConversionOCF / Net Profit
5.30×
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
CPT
CPT
Q4 25
$826.6M
Q3 25
$250.9M
Q2 25
$230.7M
Q1 25
$-63.1M
$148.2M
Q4 24
$-46.0M
$774.9M
Q3 24
$30.7M
$261.6M
Q2 24
$-36.2M
$225.1M
Q1 24
$-31.9M
$135.9M
Free Cash Flow
ACLX
ACLX
CPT
CPT
Q4 25
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
Q2 24
$-39.5M
Q1 24
$-38.3M
FCF Margin
ACLX
ACLX
CPT
CPT
Q4 25
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
Q2 24
-144.1%
Q1 24
-97.7%
Capex Intensity
ACLX
ACLX
CPT
CPT
Q4 25
Q3 25
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
Q2 24
11.7%
Q1 24
16.4%
Cash Conversion
ACLX
ACLX
CPT
CPT
Q4 25
5.30×
Q3 25
2.30×
Q2 25
2.86×
Q1 25
3.82×
Q4 24
19.04×
Q3 24
Q2 24
5.24×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons